Ricky Goldwasser
Stock Analyst at Morgan Stanley
(3.47)
# 935
Out of 4,711 analysts
245
Total ratings
64.12%
Success rate
11.22%
Average return
Main Sectors:
Stocks Rated by Ricky Goldwasser
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LH Labcorp Holdings | Maintains: Overweight | $260 → $270 | $228.61 | +18.11% | 15 | Dec 17, 2024 | |
| ACCD Accolade | Maintains: Equal-Weight | $6 → $5 | $3.48 | +43.68% | 17 | Dec 17, 2024 | |
| DOCS Doximity | Upgrades: Equal-Weight | $33 → $53 | $57.83 | -8.35% | 9 | Nov 14, 2024 | |
| UNH UnitedHealth Group | Maintains: Overweight | $615 → $610 | $500.13 | +21.97% | 15 | Oct 16, 2024 | |
| LFST LifeStance Health Group | Reiterates: Overweight | $10 | $7.29 | +37.17% | 8 | Apr 22, 2024 | |
| GDRX GoodRx Holdings | Maintains: Equal-Weight | $8 → $5.5 | $4.44 | +23.87% | 9 | Nov 10, 2023 | |
| CRL Charles River Laboratories International | Maintains: Equal-Weight | $220 → $205 | $185.77 | +10.35% | 19 | Nov 10, 2023 | |
| OSCR Oscar Health | Maintains: Equal-Weight | $5 → $7.5 | $14.09 | -46.77% | 6 | Aug 30, 2023 | |
| ALHC Alignment Healthcare | Maintains: Overweight | $19 → $12 | $10.61 | +13.10% | 8 | Aug 30, 2023 | |
| CNC Centene | Downgrades: Equal-Weight | $94 → $73 | $59.58 | +22.52% | 10 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $145 | $153.10 | -5.29% | 17 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $365 | $294.73 | +23.84% | 7 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $403 → $420 | $579.74 | -27.55% | 27 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $120 | $7.87 | +1,424.78% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $549 → $620 | $247.10 | +150.91% | 11 | Oct 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $485 → $500 | $365.96 | +36.63% | 2 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $127 → $124 | $44.36 | +179.53% | 9 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $296 → $318 | $276.92 | +14.83% | 11 | Aug 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $70 | $118.28 | -40.82% | 17 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $43 → $39 | $9.55 | +308.38% | 15 | Jul 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $182 → $195 | $197.27 | -1.15% | 6 | Oct 21, 2020 |
Labcorp Holdings
Dec 17, 2024
Maintains: Overweight
Price Target: $260 → $270
Current: $228.61
Upside: +18.11%
Accolade
Dec 17, 2024
Maintains: Equal-Weight
Price Target: $6 → $5
Current: $3.48
Upside: +43.68%
Doximity
Nov 14, 2024
Upgrades: Equal-Weight
Price Target: $33 → $53
Current: $57.83
Upside: -8.35%
UnitedHealth Group
Oct 16, 2024
Maintains: Overweight
Price Target: $615 → $610
Current: $500.13
Upside: +21.97%
LifeStance Health Group
Apr 22, 2024
Reiterates: Overweight
Price Target: $10
Current: $7.29
Upside: +37.17%
GoodRx Holdings
Nov 10, 2023
Maintains: Equal-Weight
Price Target: $8 → $5.5
Current: $4.44
Upside: +23.87%
Charles River Laboratories International
Nov 10, 2023
Maintains: Equal-Weight
Price Target: $220 → $205
Current: $185.77
Upside: +10.35%
Oscar Health
Aug 30, 2023
Maintains: Equal-Weight
Price Target: $5 → $7.5
Current: $14.09
Upside: -46.77%
Alignment Healthcare
Aug 30, 2023
Maintains: Overweight
Price Target: $19 → $12
Current: $10.61
Upside: +13.10%
Centene
Aug 30, 2023
Downgrades: Equal-Weight
Price Target: $94 → $73
Current: $59.58
Upside: +22.52%
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $145
Current: $153.10
Upside: -5.29%
Jul 14, 2023
Reiterates: Overweight
Price Target: $365
Current: $294.73
Upside: +23.84%
Jan 6, 2023
Maintains: Overweight
Price Target: $403 → $420
Current: $579.74
Upside: -27.55%
Jan 6, 2023
Maintains: Overweight
Price Target: $140 → $120
Current: $7.87
Upside: +1,424.78%
Oct 31, 2022
Maintains: Overweight
Price Target: $549 → $620
Current: $247.10
Upside: +150.91%
Oct 21, 2022
Maintains: Equal-Weight
Price Target: $485 → $500
Current: $365.96
Upside: +36.63%
Oct 11, 2022
Maintains: Overweight
Price Target: $127 → $124
Current: $44.36
Upside: +179.53%
Aug 17, 2022
Maintains: Overweight
Price Target: $296 → $318
Current: $276.92
Upside: +14.83%
Jul 14, 2022
Maintains: Overweight
Price Target: $74 → $70
Current: $118.28
Upside: -40.82%
Jul 6, 2022
Maintains: Underweight
Price Target: $43 → $39
Current: $9.55
Upside: +308.38%
Oct 21, 2020
Maintains: Overweight
Price Target: $182 → $195
Current: $197.27
Upside: -1.15%